Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry

Autor: Riccardo Morganti, Ivano Biviano, Siro Bagnoli, Francesca Calella, Sara Naldini, E.N. Lynch, Lorenzo Bertani, Linda Ceccarelli, Paolo Lionetti, Simona Maltinti, Alberto Pieraccini, G. Tapete, Moira Minciotti, Francesca De Nigris, Martina Giannotta, Francesco Costa, Maria Gloria Mumolo, Monica Milla, Silvia Rentini

Publikováno v: Inflammatory Bowel Diseases. 28:62-69

Background Few data are currently available about SB5 in inflammatory bowel diseases (IBD). The aim of this study was to assess the effectiveness and safety of SB5 in a cohort of patients with IBD in stable remission switched from the adalimumab (ADA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b74f862fee62621fb769e9647058a99
https://doi.org/10.1093/ibd/izab027

Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis

Autor: Nikolai Dyrberg Loft, Kawa Khaled Ajgeiy, Lone Skov, Mads Kirchheiner Rasmussen, Lars Erik Bryld, Lars Iversen, Tomas Norman Dam, Alexander Egeberg, Christoffer Valdemar Nissen

Publikováno v: Loft, N, Egeberg, A, Rasmussen, M K, Bryld, L E, Nissen, C V, Dam, T N, Ajgeiy, K K, Iversen, L & Skov, L 2021, ' Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis ', JAMA Dermatology, vol. 157, no. 6, pp. 676-683 . https://doi.org/10.1001/jamadermatol.2021.0221
JAMA Dermatol
Loft, N, Egeberg, A, Rasmussen, M K, Bryld, L E, Nissen, C V, Dam, T N, Ajgeiy, K K, Iversen, L & Skov, L 2021, ' Outcomes following a Mandatory Nonmedical Switch from Adalimumab Originator to Adalimumab Biosimilars in Patients with Psoriasis ', JAMA Dermatology, vol. 157, no. 6, pp. 676-683 . https://doi.org/10.1001/jamadermatol.2021.0221

Importance: The efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) in clinical trials. However, limited knowledge about real-world data exists for adalimumab biosimilars.Objective: To asses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d5105f8ab795f8d04504691c842ce34
https://pure.au.dk/portal/da/publications/outcomes-following-a-mandatory-nonmedical-switch-from-adalimumab-originator-to-adalimumab-biosimilars-in-patients-with-psoriasis(54951f16-d906-4695-b8db-48b16e6075e5).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

THE RETENTION RATE OF ETANERCEPT AND ADALIMUMAB IN FIRST-LINE AND AFTER NONMEDICAL SWITCH IN PATIENTS WITH PSORIATIC ARTHRITIS: A COMPARISON BETWEEN ORIGINATORS AND BIOSIMILARS. A SINGLE-CENTER RETROSPECTIVE STUDY.

Autor: Rella, V., Rotondo, C., Maruotti, N., Altomare, A., Erroi, F., Stefania, S., Trotta, A., Cantatore, F. P., Corrado, A.

Publikováno v: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p1794-1794, 1/2p